AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9692270
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment (CBT) plus disulfiram
Trial: 9692270
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment (CBT) plus no medication
Trial: 9692270
Drug: Twelve Step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twelve Step Facilitation (TSF) plus no medication
Trial: 28836796
Drug: Treatment Entry
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Entry Training (TEnT) (4-6 sessions)
Trial: 22336488
Drug: Eltrombopag powder
RxNorm normalized name: eltrombopag Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag powder for oral suspension (PfOS) 25 mg administered fasted
Trial: 2709216
Drug: Diflunisal 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 1,000 mg administered 30 minutes preoperatively
Trial: 2709216
Drug: Diflunisal 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 1,000 mg administered 30 minutes postoperatively
Trial: 75692
Drug: Intra-amniotic hyperosmolar
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic hyperosmolar urea and 5 mg. of prostaglandin F2alpha (PGF2alpha)
Trial: 75692
Drug: Intra-amniotic hyperosmolar
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic hyperosmolar urea and 10 mg. of prostaglandin F2alpha
Trial: 22964475
Drug: Calcium (2
RxNorm normalized name: calcium (2ξ)-D-gluco-heptonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (2 g/day) and Vitamin D3 (800 IU/day)
Trial: 19997906
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (cognitive-enhancing drug)
Trial: 11872516
Drug: Psychoeducational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational group therapy (up to 18 sessions)
Trial: 8682011
Drug: Control (non
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non fibrinolytic medical therapy)
Trial: 2233906
Drug: H. influenzae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. influenzae type b polysaccharide‐diphtheria toxoid conjugate vaccine (PRP‐D)
Trial: 2233906
Drug: H. influenzae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. influenzae type b polysaccharide‐diphtheria toxoid conjugate vaccine (PRP‐D) after three doses
Trial: 582880
Drug: Homatropine methylbromide
RxNorm normalized name: Homatropine Methylbromide
DrugBank: Homatropine methylbromide (DB00725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homatropine methylbromide plus phenobarbital in a 20% alcohol solution
Trial: 25843243
Drug: 100 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp with 270 mgI/mL iodixanol
Trial: 21252738
Drug: Oxytocin administration
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administration for 12 hours after membrane rupture
Trial: 19723905
Drug: Intravenous epoprostenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous epoprostenol (Flolan)
Trial: 15855569
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin (7.5 mg/day)
Trial: 15855569
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin (7.5 mg/day) in subgroup with IAA levels > or =80 nU/ml (n = 263)
Trial: 15855569
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in subgroup with IAA levels > or =80 nU/ml (n = 263)
Trial: 788655
Drug: Antibiotics (Ampicillin)
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics (Ampicillin)
Trial: 27590273
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed therapy with fluoxetine
Trial: 27590273
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to community mental health treatment
Trial: 15606395
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice daily for 12 weeks) + Infliximab (5 mg/kg at weeks 6, 8, and 12)
Trial: 15606395
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Infliximab (5 mg/kg at weeks 6, 8, and 12)
Trial: 15606395
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice daily for 12 weeks)
Trial: 7505563
Drug: Finasteride, 5
RxNorm normalized name: Finasteride, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride, 5 mg for 24 months
Trial: 25609176
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide injections (n = 16)
Trial: 25609176
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n = 16)
Trial: 16632411
Drug: Natural dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural dietary sources of TFA (milk fat enriched in TFA, approximately 20 g/100 g of total fatty acids)
Trial: 10811665
Drug: Protocol-based systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-based systemic and intrathecal chemotherapy + CNS irradiation (for 36 patients)
Trial: 10811665
Drug: LDH levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDH levels greater than 500 IU/L
Trial: 1482143
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of fleroxacin alone
Trial: 1482143
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of fleroxacin with 1 g of sucralfate every 6 h starting 24 h before and continuing for 48 h after fleroxacin treatment
Trial: 30766716
Drug: Follicle stimulating
RxNorm normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follicle stimulating hormone (FSH) level >/= 25.8 mIU/mL
Trial: 24803033
Drug: Sodium butyrate
RxNorm normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium butyrate 1 g, 2 g, or 4 g daily
Trial: 22030709
Drug: Fluoxetine (n=13)
RxNorm normalized name: Ammonia N 13
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n=13)
Trial: 22030709
Drug: Cognitive-Behavior Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavior Therapy (CBT) (n=13)
Trial: 20215520
Drug: Pazopanib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib therapy
Trial: 19033112
Drug: 3DCRT at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3DCRT at the total dose of 66 to 70 Gy in 33 to 35 fractions
Trial: 19033112
Drug: Stereotactic radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stereotactic radiotherapy (SRT) at the dose of 20 Gy in 4 fractions after 60 Gy 3DCRT
Trial: 31503307
Drug: Methotrexate, 25
RxNorm normalized name: Methotrexate, 25 mg/mL-NaCl 0.9% preservative-free intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate, 25 mg weekly (n=107)
Trial: 31503307
Drug: Mycophenolate mofetil,
RxNorm normalized name: Mycophenolate Mofetil, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycophenolate mofetil, 3 g daily (n=109)
Trial: 25885521
Drug: ISIS-CRPRx 100
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS-CRPRx 100 mg
Trial: 25885521
Drug: ISIS-CRPRx 200
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS-CRPRx 200 mg
Trial: 25885521
Drug: ISIS-CRPRx 400
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS-CRPRx 400 mg
Trial: 25885521
Drug: ISIS-CRPRx (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS-CRPRx (all doses)
Trial: 17184645
Drug: Medium-dose aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium-dose aspirin (325 mg)
Trial: 2123632
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no epoetin beta therapy)
Trial: 31999500
Drug: Bauhinia forficata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bauhinia forficata Link tincture (BFLT) 23.2 mg/mL
Trial: 31999500
Drug: Ethanol 81.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 81.20 g/mL
Trial: 30643228
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous endotoxin
Trial: 30643228
Drug: Baseline activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline activity of glucocorticoid receptor (GR) related TFs
Trial: 27592635
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral therapy targeting intolerance of uncertainty (CBT‐IU)
Trial: 15352909
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein > 6 mg/L
Trial: 15352909
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of erythrocyte sedimentation rate and C-reactive protein
Trial: 9878986
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tirofiban and heparin
Trial: 9878986
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose lamifiban
Trial: 9878986
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose lamifiban
Trial: 28984076
Drug: Family-Based Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Based Behavioral Treatment (FBT)
Trial: 26316194
Drug: Internet CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet CBT adjunctive to specialized headache treatment
Trial: 26316194
Drug: Specialized headache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized headache treatment alone
Trial: 23746673
Drug: Immediate total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate total provisional prosthesis on temporary immediate implants (test group, 12 patients)
Trial: 20213220
Drug: Investigational agents
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational agents
Trial: 16373258
Drug: DHEA (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (30 mg/20 mg daily for <45/≥46 years)
Trial: 16373258
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups during active treatment
Trial: 12027839
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 mg/kg/h with 5 microg/kg/h remifentanil)
Trial: 10204127
Drug: Teicoplanin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (6 mg/kg i.v. single dose)
Trial: 10204127
Drug: Cephradine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephradine (1 g i.v. + metronidazole (1 g rectally) with two further doses of cephradine and metronidazole
Trial: 2338403
Drug: Piracetam (170
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (170 mg/kg for acute treatment)
Trial: 2338403
Drug: Piracetam (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (140 mg/kg/day for chronic treatment)
Trial: 30088321
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication review and patient interview upon admission (intervention ED)
Trial: 30088321
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication review and patient interview upon admission, medication review during inpatient stay, and medication report and patient counselling at discharge (intervention STAY)
Trial: 17936154
Drug: KW-3902 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-3902 2.5 mg
Trial: 17936154
Drug: KW-3902 15
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-3902 15 mg
Trial: 17936154
Drug: KW-3902 30
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-3902 30 mg
Trial: 17936154
Drug: KW-3902 60
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-3902 60 mg
Trial: 17936154
Drug: KW-3902 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-3902 (all doses)
Trial: 17936154
Drug: KW-3902 10
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-3902 10 mg
Trial: 15378139
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of atorvastatin daily plus usual therapy
Trial: 2628706
Drug: 0.05% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% metronidazole solution (MD)
Trial: 2628706
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (MDP)
Trial: 1104059
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 1200 mg/day
Trial: 27651026
Drug: Buprenorphine (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.5, 1, and 3 μg/kg)
Trial: 27651026
Drug: Buprenorphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine plus milnacipran (25 and 50 mg)
Trial: 27651026
Drug: Milnacipran (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (25 or 50 mg)
Trial: 27651026
Drug: Milnacipran (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (50 mg)
Trial: 25322262
Drug: Aerobic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic and resistance training (50min, moderate intensity, twice a week for 6 weeks)
Trial: 22749178
Drug: 379 mg
RxNorm normalized name: Razadyne 12 MG (galantamine hydrobromide 15.379 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 379 mg of Green Tea Extract (GTE)
Trial: 19339758
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (walking with simple music)
Trial: 10223941
Drug: Rifapentine 600
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 600 mg oral dose following a high-fat breakfast
Trial: 10223941
Drug: Rifapentine 600
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 600 mg oral dose during fasting
Trial: 8582465
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg metoprolol plus 20 mg denopamine
Trial: 8582465
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg metoprolol plus denopamine placebo
Trial: 2151407
Drug: AH23848 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH23848 70 mg
Trial: 2151407
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg plus dipyridamole 75 mg
Trial: 29563108
Drug: blisibimod (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blisibimod (200 mg weekly)
Trial: 24448756
Drug: Aranesp (Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aranesp (Q weekly or Q 2 weeks)
Trial: 18408527
Drug: Olanzapine treatment
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine treatment for psychotic depression
Trial: 18408527
Drug: Cumulative olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative olanzapine dose
Trial: 1749203
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (atenolol and nifedipine)
Trial: 6810863
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SCG and theophylline
Trial: 31349978
Drug: Intravenous Dodecafluoropentane
RxNorm normalized name: Dodecafluoropentane
DrugBank: Perflenapent (DB11625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Dodecafluoropentane emulsion (DDFPe)
Trial: 31349978
Drug: High-dose DDFPe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DDFPe
Trial: 28324038
Drug: Exenatide plus
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide plus pioglitazone (combination therapy)
Trial: 28324038
Drug: Basal plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal plus prandial insulin (insulin therapy)
Trial: 21594619
Drug: Selumetinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (100 mg oral twice daily)
Trial: 21594619
Drug: Capecitabine (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,250 mg/m² oral twice daily)
Trial: 19349375
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion (3 doses of 250 mg/kg per dose, 1 mL/kg per dose, 24 hours apart)
Trial: 19349375
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (3 doses of 1 mL/kg per dose, 24 hours apart)
Trial: 17224418
Drug: Active therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active therapy (Pm ON)
Trial: 17224418
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (Pm OFF)
Trial: 14684561
Drug: rhDNase (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhDNase (2.5 mg/day)
Trial: 12162793
Drug: Desloratadine 5-20
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5-20 mg
Trial: 12162793
Drug: Desloratadine 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5, 7.5, and 20 mg
Trial: 12162793
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg QD
Trial: 9839823
Drug: bupivacaine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 150 mg + morphine 4 mg
Trial: 9839823
Drug: bupivacaine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 150 mg + morphine 4 mg + methylprednisolone 40 mg
Trial: 7666668
Drug: MFC +
RxNorm normalized name: Metformin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFC + continuous oral 5-FU (Group A)
Trial: 7666668
Drug: MFC +
RxNorm normalized name: Metformin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFC + continuous oral UFT (Group B)
Trial: 7666668
Drug: MFC +
RxNorm normalized name: Metformin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFC + continuous oral 5-FU (Group A) at CAD
Trial: 7666668
Drug: MFC +
RxNorm normalized name: Metformin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFC + continuous oral UFT (Group B) at CAD
Trial: 7666668
Drug: MFC +
RxNorm normalized name: Metformin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFC + continuous oral 5-FU (Group A) at CIH
Trial: 7666668
Drug: MFC +
RxNorm normalized name: Metformin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFC + continuous oral UFT (Group B) at NCC
Trial: 25559495
Drug: Multitiered oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multitiered oral health educational program for care staff
Trial: 8665335
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (10‐30 mg four times a day)
Trial: 2005708
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms desmopressin spray
Trial: 6364441
Drug: Naloxone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (8 mg loading dose followed by 5.6 mg/h continuous infusion from midnight until 10 am)